Letter to the editorSerum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis
Section snippets
Methods
We included patients who met modified New York criteria for AS and who were not receiving immunomodulating drugs or drugs known to affect bone metabolism. Age- and sex-matched controls were selected among untreated individuals who had no inflammatory or bone disease.
The following data were collected in each patient: disease duration, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global score
Results
We included 28 patients with AS (22 men and 6 women), whose mean age was 42 years and mean disease duration 14 years. Mean values of disease-related variables were as follows: BASDAI, 42.0 mm; BASFI, 35.5 mm; BAS-G, 49.6 mm; ESR, 32.7 mm; CRP, 21.7 mg/L; and IgA, 2.79 g/L. Table 1 lists the main results. Serum IL-17 levels were significantly higher in the patients than the controls. No distinctive features were identified in the patients with the highest IL-17 levels. Non-significant serum BMP-7
Discussion
In a group of patients with established AS and evidence of active inflammation (ESR ≥ 30 mm, CRP ≥ 20 mg/L, and BASDAI ≥ 40), the bone formation marker BALP was decreased and the bone resorption marker TRAP was increased compared to controls. In the patients, sCTX correlated with ESR. These findings are consistent with earlier data and with the occurrence of bone loss in some AS patients [1], [2].
Serum IL-17 levels were significantly higher in AS patients than in controls. They failed to correlate with
References (10)
Osteoporosis and ankylosing spondylitis
Joint Bone Spine
(2004)IL-17 in rheumatoid arthritis: a new target for treatment or just another cytokine?
Joint Bone Spine
(2004)- et al.
Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1
Am J Pathol
(2005) - et al.
Expression of interleukin-17B in mouse embryonic limb buds and regulation by BMP-7 and bFGF
Biochem Biophys Res Commun
(2005) Bone loss in ankylosing spondylitis: can we put the puzzle together?
J Rheumatol
(2005)
Cited by (153)
Recent Updates in Juvenile Spondyloarthritis
2021, Rheumatic Disease Clinics of North AmericaGut microbiota–microRNA interactions in ankylosing spondylitis
2021, Autoimmunity ReviewsCitation Excerpt :Research findings in AS patients found that peripheral blood concentrations of Th17, Th22, and γδ T cells were elevated, and excessive IL-17 levels were observed [17,18]. In the PBMC of AS patients, HLA-B27 FHC-sensitive KIR3DL2+ Th17 cells have also been shown to expand [18]. Multiple studies have confirmed the possible correlation between the gut microbiota and the IL-23/IL-17 network in the pathogenesis of AS in recent years.
Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers
2021, Autoimmunity ReviewsThe Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities
2024, Rheumatology and Therapy